A Deep Dive into the Inclusivity of Clinical Trials and Patient Education in RCC
The article from Cancer Therapy Advisor stresses the pressing need for real-world data on renal cell carcinoma (RCC). It highlights the ongoing efforts to make clinical trials more inclusive and to better understand patient experiences across different countries.
HCN Medical Memo
For healthcare professionals, this article underscores the importance of broadening the criteria for clinical trials to better represent real-world patient populations. This could lead to more useful data and improved patient care. It also highlights the need for comprehensive patient education in community-based care of RCC.
- A significant proportion of RCC studies utilize overly restrictive eligibility criteria.
- The most common exclusion criteria include a history of HIV infection or AIDS, known acute chronic hepatitis B or C infection, symptomatic brain metastasis or a history of it, and concurrent malignancies.
- The International Kidney Cancer Coalition conducted its third biennial Global Patient Survey on the diagnosis, treatment, and overall disease burden of RCC.
- The outcomes of patients with brain metastases of RCC are not well known because these patients are typically excluded from clinical trials.
Renal cell carcinoma accounts for approximately 90% of all kidney cancers.
More on Kidney Cancer/RCC